Institut de la Vision, Sorbonne Université, INSERM, CNRS, 17, Rue Moreau, Paris 75012, France.
INSERM U861, UEVE, CECS, AFM, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, Corbeil-Essonnes 91100, France.
Stem Cell Reports. 2018 Sep 11;11(3):665-680. doi: 10.1016/j.stemcr.2018.07.005. Epub 2018 Aug 9.
Photoreceptor degenerative diseases are a major cause of blindness for which cell replacement is one of the most encouraging strategies. For stem cell-based therapy using human induced pluripotent stem cells (hiPSCs), it is crucial to obtain a homogenous photoreceptor cell population. We confirmed that the cell surface antigen CD73 is exclusively expressed in hiPSC-derived photoreceptors by generating a fluorescent cone rod homeobox (Crx) reporter hiPSC line using CRISPR/Cas9 genome editing. We demonstrated that CD73 targeting by magnetic-activated cell sorting (MACS) is an effective strategy to separate a safe population of transplantable photoreceptors. CD73+ photoreceptor precursors can be isolated in large numbers and transplanted into rat eyes, showing capacity to survive and mature in close proximity to host inner retina of a model of photoreceptor degeneration. These data demonstrate that CD73+ photoreceptor precursors hold great promise for a future safe clinical translation.
光感受器退行性疾病是导致失明的主要原因之一,而细胞替代是最有前途的策略之一。对于基于干细胞的治疗,使用人诱导多能干细胞(hiPSC),获得同质的光感受器细胞群体至关重要。我们通过使用 CRISPR/Cas9 基因组编辑生成荧光视锥杆同源盒(Crx)报告 hiPSC 系,证实细胞表面抗原 CD73 仅在 hiPSC 衍生的光感受器中表达。我们证明,通过磁激活细胞分选(MACS)靶向 CD73 是分离安全的可移植光感受器群体的有效策略。可以大量分离 CD73+光感受器前体,并将其移植到大鼠眼中,在光感受器退行性病变模型中,显示出在与宿主内视网膜接近的位置存活和成熟的能力。这些数据表明,CD73+光感受器前体具有很大的临床转化为安全治疗的潜力。